ArticleEndocrinology, diabetes & metabolism2026
Impact of Short-Term Insulin Pump Therapy on Cardiometabolic Index in Patients With Newly Diagnosed Type 2 Diabetes Mellitus.
Article in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study aims to investigate the changes in cardiometabolic index (CMI) levels in newly diagnosed type 2 diabetes mellitus (T2DM) patients before and after undergoing short-term continuous subcutaneous insulin infusion (CSII) intensive treatment and analyse its correlation with insulin resistance.
methodsThis study retrospectively collected data from 604 patients who were initially diagnosed with T2DM and received short-term CSII treatment during their hospitalisation in the Endocrinology Department of the Affiliated Hospital of Jiangsu University. Clinical data, blood glucose, insulin, C-peptide, blood biochemistry, and other indicators were collected before and after treatment, and CMI was calculated.
resultsShort-term CSII treatment significantly improved blood glucose levels, insulin resistance, and pancreatic β-cell function in T2DM patients, while downregulating the CMI index (p = 0.002). Correlation analysis showed a positive correlation between CMI and HOMA-IR (p < 0.001) and a negative correlation between CMI and HOMA-β (p = 0.008). Stepwise linear regression model analysis revealed that CMI was independently associated with fasting C-peptide (FCP) before treatment (β = 0.291, p < 0.001); after treatment, CMI was associated with FCP (β = 0.160, p < 0.001) and HOMA-IR (β = 0.159, p < 0.001).
conclusionAfter short-term intensive CSII treatment, the CMI level in newly diagnosed T2DM patients significantly decreased, indicating that intensive CSII treatment may have certain significance in improving cardiometabolic function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.